CO2022004596A2 - Tak-925 para uso en el tratamiento de la narcolepsia - Google Patents

Tak-925 para uso en el tratamiento de la narcolepsia

Info

Publication number
CO2022004596A2
CO2022004596A2 CONC2022/0004596A CO2022004596A CO2022004596A2 CO 2022004596 A2 CO2022004596 A2 CO 2022004596A2 CO 2022004596 A CO2022004596 A CO 2022004596A CO 2022004596 A2 CO2022004596 A2 CO 2022004596A2
Authority
CO
Colombia
Prior art keywords
narcolepsy
compound
tak
treatment
subject
Prior art date
Application number
CONC2022/0004596A
Other languages
English (en)
Inventor
Deborah Hartman
Rebecca Evans
Helene Faessel
Shinichiro Tanaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2022004596A2 publication Critical patent/CO2022004596A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

RESUMEN Se describe un método para tratar la narcolepsia tipo 1 en un sujeto que lo necesite, que comprende administrar al sujeto una cantidad efectiva de 3-((metilsulfonil)amino)-2-(((4-fenilciclohexil)oxi)metil)piperidina-1-carboxilato de metilo (Compuesto (I)), o una sal de este, en donde la concentración plasmática del Compuesto (I) es de aproximadamente 5,04 ng/mL o más durante aproximadamente 1 hora o más. También se describen composiciones para tratar la narcolepsia tipo 1 que comprenden el Compuesto (I)
CONC2022/0004596A 2019-09-13 2022-04-11 Tak-925 para uso en el tratamiento de la narcolepsia CO2022004596A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900298P 2019-09-13 2019-09-13
US202063031686P 2020-05-29 2020-05-29
PCT/IB2020/058483 WO2021048822A1 (en) 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy

Publications (1)

Publication Number Publication Date
CO2022004596A2 true CO2022004596A2 (es) 2022-08-30

Family

ID=72560858

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0004596A CO2022004596A2 (es) 2019-09-13 2022-04-11 Tak-925 para uso en el tratamiento de la narcolepsia

Country Status (11)

Country Link
US (1) US20220339143A1 (es)
EP (1) EP4028004A1 (es)
JP (1) JP2022547711A (es)
KR (1) KR20220062012A (es)
CN (1) CN114980892A (es)
AU (1) AU2020346456A1 (es)
BR (1) BR112022004587A2 (es)
CA (1) CA3154321A1 (es)
CO (1) CO2022004596A2 (es)
MX (1) MX2022003018A (es)
WO (1) WO2021048822A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313045A1 (en) * 2021-04-02 2024-02-07 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for post operation recovery
WO2024095158A1 (en) * 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
WO1998008868A1 (en) 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
WO2001000663A2 (en) 1999-06-28 2001-01-04 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US10188652B2 (en) * 2014-10-23 2019-01-29 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
MX2017016413A (es) * 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
DK3411358T3 (da) * 2016-02-04 2022-01-17 Takeda Pharmaceuticals Co Substitueret piperidinforbindelse og anvendelse deraf.

Also Published As

Publication number Publication date
JP2022547711A (ja) 2022-11-15
WO2021048822A1 (en) 2021-03-18
CN114980892A (zh) 2022-08-30
EP4028004A1 (en) 2022-07-20
US20220339143A1 (en) 2022-10-27
BR112022004587A2 (pt) 2022-06-14
AU2020346456A1 (en) 2022-04-14
CA3154321A1 (en) 2021-03-18
MX2022003018A (es) 2022-06-14
KR20220062012A (ko) 2022-05-13

Similar Documents

Publication Publication Date Title
CO2022004596A2 (es) Tak-925 para uso en el tratamiento de la narcolepsia
UY38059A (es) Heterociclos sustituidos como agentes antivirales
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
UY37998A (es) Agentes antivirales contra la hepatitis b
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
CL2008001194A1 (es) Composicion farmaceutica que comprende florfenico, una ciclodextrina y agua, un solvente y7o una mezcka de los mismos, con al menos 5% de solvente; kit que la contiene; complejo de florfenicol, util para tratr enfermedades respiratorias en animales
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
EA201170969A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
PE20211305A1 (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
PE20060364A1 (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
ATE540667T1 (de) Verbindungen mit kühlender wirkung
PE20212070A1 (es) Moduladores de trex1
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
AR043444A1 (es) Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
AR119479A1 (es) Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
BRPI0520167A2 (pt) formulaÇÕes aprimoradas de fenofibrato contendo mentol ou uma mistura de peg/poloxÂmero
PE20230180A1 (es) Uso de bi853520 en tratamiento contra el cancer
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
BR112022013547A2 (pt) Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR128257A1 (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
UY28372A1 (es) Agentes terapéuticos